Significance of Lipopolysaccharides in Gastric Cancer and their Potential as a Biomarker for Nivolumab Sensitivity
Authors:
- Nobuhiro NakazawaNNNobuhiro Nakazawa
- Takehiko YokoboriTakehiko Yokobori
- Makoto SohdaMSMakoto Sohda
- Nobuhiro HosoiNHNobuhiro Hosoi
- Takayoshi WatanabeTWTakayoshi Watanabe
- Yuki ShimodaYSYuki Shimoda
- Munenori IdeMIMunenori Ide
- Akihiko SanoASAkihiko Sano
- Makoto SakaiMSMakoto Sakai
- Bilguun Erkhem-OchirBEBilguun Erkhem-Ochir
- Hiroomi OgawaHOHiroomi Ogawa
- Ken ShirabeKSKen Shirabe
Preprint
- 21 June 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Lipopolysaccharides are a type of polysaccharide mainly present in the bacterial outer membrane of Gram-negative bacteria. Recent studies have revealed that lipopolysaccharides contribute to the immune response of the host by functioning as a cancer antigen. We retrospectively recruited 198 patients with gastric cancer who underwent surgery. The presence of lipopolysaccharides was determined using immunohistochemical staining, with the intensity score indicating positivity. The relationship between lipopolysaccharides and CD8, PD-L1, TGFBI (a representative downstream gene of TGF-β signaling), E-cadherin, and claudin-4 (epithelial–mesenchymal transition markers) was also investigated. Thereafter, we identified 20 patients with advanced gastric cancer receiving nivolumab and investigated the relationship between lipopolysaccharides and nivolumab sensitivity. After staining for lipopolysaccharides in the nucleus of cancer cells, 150 negative (75.8%) and 48 positive cases (24.2%) were found. The lipopolysaccharide-positive group showed increased cancer stromal TGFBI expression (p < 0.0001) and PD-L1 expression in cancer cells (p = 0.0029). Lipopolysaccharide positivity was significantly correlated with decreased E-cadherin expression (p = 0.0055) and claudin-4 expression (p = 0.029); however, no significant correlation was found between lipopolysaccharide expression and overall survival rate (p = 0.71). Among cases receiving nivolumab, the lipopolysaccharide-negative and -positive groups had a disease control rate of 66.7% and 11.8%, respectively (p = 0.049). Lipopolysaccharide positivity was associated with TGF-β signaling and epithelial–mesenchymal transition and was considered to promote therapeutic resistance to nivolumab.Keywords
All Related Versions
This publication has 30 references indexed in Scilit:
- Lipopolysaccharide exacerbates to the migration, invasion, and epithelial‐mesenchymal transition of esophageal cancer cells by TLR4 / NF‐κB axisEnvironmental Toxicology, 2023
- Cytoplasmic localization of connexin 26 suppresses transition of β‐catenin into the nucleus in intestinal‐ and mix‐type gastric cancerAnnals of Gastroenterological Surgery, 2022
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialThe Lancet, 2021
- EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancerNature Communications, 2018
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Autophagy impairment byHelicobacter pylori-induced methylation silencing ofMAP1LC3Av1promotes gastric carcinogenesisInternational Journal of Cancer, 2017
- TNF-α-inducing protein of Helicobacter pylori induces epithelial-mesenchymal transition (EMT) in gastric cancer cells through activation of IL-6/STAT3 signaling pathwayBiochemical and Biophysical Research Communications, 2017
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Epithelial–mesenchymal transition and the invasive potential of tumorsTrends in Molecular Medicine, 2008
- NF-κB as a therapeutic target in cancerTrends in Molecular Medicine, 2002